Dr. Smith on the Development of Active Therapeutic Combinations in Acute Myeloid Leukemia

Video

In Partnership With:

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, discusses developing active therapeutic combinations for the treatment of patients with acute myeloid leukemia

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Comprehensive Cancer Center, discusses developing active therapeutic combinations for the treatment of patients with acute myeloid leukemia (AML).

At the 2017 ASH Annual Meeting, researchers discussed that clinical trials have been focused on developing active therapeutic combinations. Smith cites the benefit of such an approach in the recent FDA approval and application of midostaurin (Rydapt), an inactive single agent, in combination with chemotherapy. This resulted in an increase in overall survival (OS) in a randomized upfront trial compared to chemotherapy alone, demonstrating a 7% absolute benefit in 4-year OS.

Drugs that may not be ideal alone, when combined with the right agents, may be able to produce better outcomes. Ongoing trials of these more active second-generation FLT3 inhibitors are currently accruing in the upfront setting and the relapsed/refractory setting. These include upfront combinations with gilteritinib, quizartinib, induction chemotherapy, and hypomethylating agents.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD